Developer docs
API playgroundTry for free, no card

Search company profiles

Amphastar Pharmaceuticals

Full company profile

uuid0000usf

Namestring
Amphastar Pharmaceuticals
Legal namestring
Amphastar Pharmaceuticals, Inc.
Websiteurl
amphastar.com
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a vertically integrated specialty biopharmaceutical company founded in 1996 by Dr. Jack Zhang and Dr. Mary Luo and headquartered in Rancho Cucamonga, California. The company develops, manufactures, and markets injectable, intranasal, and inhalation pharmaceutical products — including complex biologics derived from living cells or organisms, proteins, and interchangeable biosimilars — across eight technological platforms spanning particle engineering (nm to µm), sustained-release formulations, immunogenicity characterization, combination products, and proprietary drug delivery systems. The portfolio combines branded proprietary products (BAQSIMI glucagon nasal powder, Primatene MIST OTC epinephrine inhaler, Rextovy OTC naloxone nasal spray, Cortrosyn, Amphadase) with a generic injectable and inhalation portfolio (Iron Sucrose, Teriparatide, Albuterol Sulfate, Ipratropium Bromide HFA, Glucagon, Epinephrine, Enoxaparin Sodium, Naloxone Injection), and the company manufactures its own active pharmaceutical ingredients through wholly owned subsidiaries in Nanjing, China and Eragny-sur-Epte, France.

The business operates a sales-led go-to-market model distributing prescription products through direct field sales to hospitals and urgent care settings, while OTC products (Primatene MIST, Rextovy) are distributed through retail pharmacies, convenience stores, and online channels. Pricing for prescription products is negotiated through healthcare providers, insurance plans, and pharmacy benefit managers and is not publicly disclosed. The company employs 1,001-5,000 staff across six cGMP-compliant facilities — three in California (Rancho Cucamonga HQ/injectables, South El Monte/IMS sterile injectables, Chino R&D), one in Canton, Massachusetts (Armstrong/inhalation MDIs and nasal sprays), one in Nanjing, China (API manufacturing), and one in Eragny-sur-Epte, France (recombinant human insulin API). FY2025 revenue was $719.9 million with GAAP net income of $98.1 million, reflecting a 2% top-line decline from FY2024 driven by generic pricing pressure partially offset by BAQSIMI growth of 46% to $185.4 million.

Revenue mechanics rest on three streams: (1) generic pharmaceutical products sold one-time to hospitals and urgent care, (2) proprietary branded products with established market positions in glucagon, OTC asthma, and now OTC naloxone, and (3) internal API production supplying both operations and external customers. Customer segments are horizontally distributed across hospital systems, retail pharmacy chains, and end-patient consumers for OTC products, with no disclosed customer concentration. The company is publicly traded with approximately 65% institutional ownership, completed its IPO in April 2014, and raised $300 million in convertible senior notes in September 2023 to support debt repayment, share repurchases, and general corporate purposes including potential M&A.

Short descriptiontext

Amphastar Pharmaceuticals is a vertically integrated specialty biopharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal, and inhalation pharmaceutical products, serving hospitals, urgent care facilities, retail pharmacies, and patients across the US, China, and France.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRancho Cucamonga, United States
HQ citystring
Rancho Cucamonga
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic injectables, inhalation pharmaceuticals, intranasal drug delivery, biopharmaceutical manufacturing, specialty pharmaceutical products
Industry5 codes
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Products
TypeOne Time License
Description

Amphastar generates revenue from manufacturing and selling generic injectable, inhalation, and intranasal products to hospitals and urgent care settings. Products include iron sucrose injection, various injectable medications, and generic respiratory products.

amphastar.com
2Proprietary/Branded Products
TypeOne Time License
Description

Revenue from proprietary branded products including BAQSIMI (glucagon nasal powder), Primatene MIST (OTC epinephrine inhaler), and other proprietary pharmaceutical products sold through healthcare providers and retail channels.

amphastar.com
3Active Pharmaceutical Ingredients (APIs)
TypeOne Time License
Description

Amphastar manufactures and supplies APIs to internal operations and potentially external customers. APIs manufactured include enoxaparin sodium, isoproterenol hydrochloride, hyaluronidase, cosyntropin, human insulin and insulin analogs, and vasopressin.

pharmiweb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products - pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Product pricing determined through healthcare system, insurance coverage, and pharmacy channels

amphastar.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1BAQSIMI
Description

Glucagon nasal powder for treatment of severe hypoglycemia - #1 prescribed glucagon in the US

amphastar.com
+6 more records
Core offering1 text field

Amphastar Pharmaceuticals develops, manufactures, and markets a diversified portfolio of injectable, intranasal, and inhalation pharmaceutical products, including generics, complex biologics, biosimilars, and proprietary drugs. The company sells generic prescription products to hospitals and urgent care settings, OTC branded products such as Primatene MIST and Rextovy through retail channels, and also produces active pharmaceutical ingredients (APIs) for internal and external customers. It operates six cGMP manufacturing and research facilities across the United States, China, and France.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • BAQSIMI achieved $185.4 million in full-year 2025 revenues, up 46% year-over-year
+3 more records
Product overview1 text field

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets a diversified portfolio of generic and proprietary pharmaceutical products. The company's offerings span injectable, intranasal, and inhalation products, along with complex biologics derived from living cells or organisms. Key proprietary products include BAQSIMI® (glucagon nasal powder), Primatene® MIST (OTC asthma inhaler), and Rextovy® (naloxone nasal spray). The generic portfolio includes iron sucrose injection, teriparatide injection, albuterol sulfate inhalation aerosol, epinephrine injection, enoxaparin sodium, and various other injectable medications. Amphastar also manufactures active pharmaceutical ingredients (APIs) including insulin, hyaluronidase, and vasopressin through its subsidiaries, and operates a device laboratory for combination products (pre-filled syringes, injection pens, nasal sprays, MDIs, and DPIs). The company operates six manufacturing facilities across the US, China, and France.

Product and service14 records
1BAQSIMI® (glucagon nasal powder)
CategoryProprietary Branded Pharmaceutical
Description

Glucagon nasal powder 3 mg; the first and only dry nasal spray to treat very low blood sugar (severe hypoglycemia). Marketed to healthcare providers for patients with diabetes.

2Primatene® MIST (Epinephrine Inhalation Aerosol)
CategoryOTC Branded Pharmaceutical
Description

Epinephrine inhalation aerosol 0.125 mg per spray; the only FDA-approved over-the-counter asthma inhaler, sold directly to consumers via retail pharmacies, convenience stores, and online retailers.

3Iron Sucrose Injection, USP
CategoryGeneric Injectable Pharmaceutical
Description

Generic iron replacement injection indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD); available in 50 mg/2.5 mL, 100 mg/5 mL, and 200 mg/10 mL single-dose vials. Sold to hospitals, infusion centers, and nephrology practices.

4Teriparatide Injection
CategoryGeneric Combination Product
Description

560 mcg/2.24 mL (250 mcg/mL) teriparatide in a single-patient-use prefilled pen delivering 28 daily doses of 20 mcg; bioequivalent to Eli Lilly's FORTEO, indicated for osteoporosis treatment in postmenopausal women and men at high risk for fracture.

5Rextovy® (Naloxone HCl Nasal Spray)
CategoryOTC Branded Pharmaceutical
Description

4 mg naloxone hydrochloride nasal spray for emergency treatment of opioid overdose; FDA-approved for OTC sale, allowing direct consumer purchase without a prescription at pharmacies, convenience stores, and online retailers.

6Ipratropium Bromide HFA Inhalation Aerosol (AMP-007)
CategoryGeneric Inhalation Pharmaceutical
Description

17 mcg per actuation generic inhalation aerosol bioequivalent to Boehringer Ingelheim's Atrovent HFA, used for maintenance treatment of bronchospasm associated with COPD; first ANDA applicant entitled to 180 days of generic exclusivity.

7Albuterol Sulfate Inhalation Aerosol
CategoryGeneric Inhalation Pharmaceutical
Description

90 mcg/actuation 8.5 g metered dose inhaler used for respiratory treatment; generic inhalation product for hospitals, urgent care, and patients with asthma or COPD.

8Glucagon for Injection
CategoryGeneric Injectable Pharmaceutical
Description

Generic glucagon for injection bioequivalent and therapeutically equivalent to Lilly's Glucagon Emergency Kit; used for treatment of severe hypoglycemia and as a diagnostic aid.

9Epinephrine Injection, USP (Luer-Jet)
CategoryGeneric Injectable Pharmaceutical
Description

Epinephrine 0.1 mg/mL injection in the Luer-Jet delivery system; indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

10Enoxaparin Sodium Injection
CategoryGeneric Injectable Pharmaceutical
Description

Generic low molecular weight heparin (anticoagulant) injection with safety device; used for prevention and treatment of blood clots (DVT/PE) in hospital and outpatient settings.

11Cortrosyn® (Cosyntropin) for Injection
CategoryBranded Injectable Pharmaceutical
Description

Cosyntropin 0.25 mg with 10 mg mannitol for injection; used for ACTH stimulation testing to diagnose adrenal and pituitary gland disorders such as Addison's disease.

12Amphadase® (Hyaluronidase Injection, USP)
CategoryBranded Injectable Pharmaceutical
Description

Hyaluronidase injection used for drug dispersion, injectable therapies, surgical applications, aesthetic medicine, and management of skin and ophthalmic disorders.

13Naloxone Hydrochloride Injection, USP
CategoryGeneric Injectable Pharmaceutical
Description

Generic opioid antagonist injection used for emergency treatment of opioid overdose in hospital, emergency, and pre-hospital settings.

14Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredient Supply
Description

Active pharmaceutical ingredients manufactured at cGMP facilities in Nanjing, China (Amphastar Nanjing Pharmaceuticals) and Eragny-sur-Epte, France (Amphastar France Pharmaceuticals), including Enoxaparin Sodium, Isoproterenol Hydrochloride, Hyaluronidase, Cosyntropin, Human Insulin and insulin analogs, and Vasopressin; supplied to internal operations and external pharmaceutical customers.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a synthetic human ACTH analog designated AMP-110, covering the United States and Canada markets. The deal involves a $2 million upfront payment, with potential additional payments of up to $14 million in development milestones, $75 million in sales milestones, and royalty payments capped at $7.5 million annually and $60 million total. AMP-110 is designed for inflammatory and autoimmune conditions and is currently in early-phase clinical development, with the U.S. ACTH market having exceeded $684 million in 2024. The agreement also grants Hanxin a non-exclusive license to certain Amphastar intellectual property for development and commercialization outside the U.S. and Canada.

za.investing.com
2Nanjing Anji Biotechnology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Amphastar signed a licensing agreement with Nanjing Anji Biotechnology to develop peptides. The partnership expands Amphastar's pipeline development capabilities in the peptide drug space.

tradingview.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hikma is a global generic injectable, inhalation, and intranasal pharmaceutical manufacturer with a comparable product portfolio across hospital and respiratory channels. It directly overlaps Amphastar's core generics-plus-specialty franchise and similar US distribution model.

2Hospira (Pfizer)
TypeBroad incumbent
Description

Hospira, acquired by Pfizer in 2015, is the largest US sterile injectable manufacturer. It is the broad incumbent against which Amphastar's IMS subsidiary competes in hospital injectables and is a structural benchmark for Amphastar's generic injectable economics.

TypeBroad incumbent
Description

Teva is the world's largest generic drug maker with significant sterile injectable and respiratory (ProAir) franchises. It overlaps Amphastar across generic injectables, MDIs, and biosimilar development, and serves as a broader-sector reference point.

TypeBroad incumbent
Description

Viatris (Mylan-Upjohn combination) has a broad generic injectable, biosimilar, and branded specialty portfolio with strong hospital channel presence. Comparable to Amphastar across sterile injectables and complex generics, though materially larger and more diversified.

5Sandoz
TypeBroad incumbent
Description

Sandoz, Novartis's generics and biosimilars spin-off, is a leading global player in sterile injectables and biosimilars including insulins. Directly comparable to Amphastar's generic injectable and biosimilar insulin platform at larger scale.

TypeDirect peer
Description

ANI is a US specialty generic manufacturer with a strong injectable, inhalation, and niche branded portfolio serving hospital and specialty pharmacies. Closely comparable to Amphastar in business model, customer mix, and product complexity.

TypeDirect peer
Description

Lannett is a US-focused generic pharmaceutical company with significant presence in sterile injectables and oral solids. Comparable in scale and channel focus, though with a heavier oral generics mix.

8Endo International
TypeDirect peer
Description

Endo operates a US sterile injectable franchise (through Par Sterile) alongside specialty/branded products. The injectable segment is a direct comparable to Amphastar's IMS hospital business, though Endo's portfolio is broader and includes branded pain and urology franchises.

TypeDirect peer
Description

Dr. Reddy's is a major India-based generics manufacturer with a sizable sterile injectable and biosimilar business targeting US hospital channels. Highly comparable to Amphastar across complex generics, injectables, and respiratory products.

TypeEmerging player
Description

Aspen is a South Africa-based specialty and generic pharmaceutical company with a growing sterile injectable portfolio and US presence. It is comparable to Amphastar as a non-traditional generics competitor expanding into complex injectables, though smaller in US hospital share.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amphastar Pharmaceuticals

Specialty Pharmaceuticalsamphastar.com

Amphastar Pharmaceuticals is a vertically integrated specialty biopharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal, and inhalation pharmaceutical products, serving hospitals, urgent care facilities, retail pharmacies, and patients across the US, China, and France.

What Amphastar Pharmaceuticals does

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a vertically integrated specialty biopharmaceutical company founded in 1996 by Dr. Jack Zhang and Dr. Mary Luo and headquartered in Rancho Cucamonga, California. The company develops, manufactures, and markets injectable, intranasal, and inhalation pharmaceutical products — including complex biologics derived from living cells or organisms, proteins, and interchangeable biosimilars — across eight technological platforms spanning particle engineering (nm to µm), sustained-release formulations, immunogenicity characterization, combination products, and proprietary drug delivery systems. The portfolio combines branded proprietary products (BAQSIMI glucagon nasal powder, Primatene MIST OTC epinephrine inhaler, Rextovy OTC naloxone nasal spray, Cortrosyn, Amphadase) with a generic injectable and inhalation portfolio (Iron Sucrose, Teriparatide, Albuterol Sulfate, Ipratropium Bromide HFA, Glucagon, Epinephrine, Enoxaparin Sodium, Naloxone Injection), and the company manufactures its own active pharmaceutical ingredients through wholly owned subsidiaries in Nanjing, China and Eragny-sur-Epte, France.

The business operates a sales-led go-to-market model distributing prescription products through direct field sales to hospitals and urgent care settings, while OTC products (Primatene MIST, Rextovy) are distributed through retail pharmacies, convenience stores, and online channels. Pricing for prescription products is negotiated through healthcare providers, insurance plans, and pharmacy benefit managers and is not publicly disclosed. The company employs 1,001-5,000 staff across six cGMP-compliant facilities — three in California (Rancho Cucamonga HQ/injectables, South El Monte/IMS sterile injectables, Chino R&D), one in Canton, Massachusetts (Armstrong/inhalation MDIs and nasal sprays), one in Nanjing, China (API manufacturing), and one in Eragny-sur-Epte, France (recombinant human insulin API). FY2025 revenue was $719.9 million with GAAP net income of $98.1 million, reflecting a 2% top-line decline from FY2024 driven by generic pricing pressure partially offset by BAQSIMI growth of 46% to $185.4 million.

Revenue mechanics rest on three streams: (1) generic pharmaceutical products sold one-time to hospitals and urgent care, (2) proprietary branded products with established market positions in glucagon, OTC asthma, and now OTC naloxone, and (3) internal API production supplying both operations and external customers. Customer segments are horizontally distributed across hospital systems, retail pharmacy chains, and end-patient consumers for OTC products, with no disclosed customer concentration. The company is publicly traded with approximately 65% institutional ownership, completed its IPO in April 2014, and raised $300 million in convertible senior notes in September 2023 to support debt repayment, share repurchases, and general corporate purposes including potential M&A.

Amphastar Pharmaceuticals firmographics

Firmographics
Name
Amphastar Pharmaceuticals
Legal name
Amphastar Pharmaceuticals, Inc.
Website
https://amphastar.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
251–500 employees
Short description
Amphastar Pharmaceuticals is a vertically integrated specialty biopharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal, and inhalation pharmaceutical products, serving hospitals, urgent care facilities, retail pharmacies, and patients across the US, China, and France.
Ownership category
akta.pro rank

Amphastar Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic injectables
  • Inhalation pharmaceuticals
  • Intranasal drug delivery
  • Biopharmaceutical manufacturing
  • Specialty pharmaceutical products

Where Amphastar Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Rancho Cucamonga
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Amphastar Pharmaceuticals business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Pharmaceutical Products: Amphastar generates revenue from manufacturing and selling generic injectable, inhalation, and intranasal products to hospitals and urgent care settings. Products include iron sucrose injection, various injectable medications, and generic respiratory products.
  2. Proprietary/Branded Products: Revenue from proprietary branded products including BAQSIMI (glucagon nasal powder), Primatene MIST (OTC epinephrine inhaler), and other proprietary pharmaceutical products sold through healthcare providers and retail channels.
  3. Active Pharmaceutical Ingredients (APIs): Amphastar manufactures and supplies APIs to internal operations and potentially external customers. APIs manufactured include enoxaparin sodium, isoproterenol hydrochloride, hyaluronidase, cosyntropin, human insulin and insulin analogs, and vasopressin.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceutical products - pricing not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Amphastar Pharmaceuticals product offering

Product offering

Core offering

Amphastar Pharmaceuticals develops, manufactures, and markets a diversified portfolio of injectable, intranasal, and inhalation pharmaceutical products, including generics, complex biologics, biosimilars, and proprietary drugs. The company sells generic prescription products to hospitals and urgent care settings, OTC branded products such as Primatene MIST and Rextovy through retail channels, and also produces active pharmaceutical ingredients (APIs) for internal and external customers. It operates six cGMP manufacturing and research facilities across the United States, China, and France.

Product overview

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets a diversified portfolio of generic and proprietary pharmaceutical products. The company's offerings span injectable, intranasal, and inhalation products, along with complex biologics derived from living cells or organisms. Key proprietary products include BAQSIMI® (glucagon nasal powder), Primatene® MIST (OTC asthma inhaler), and Rextovy® (naloxone nasal spray). The generic portfolio includes iron sucrose injection, teriparatide injection, albuterol sulfate inhalation aerosol, epinephrine injection, enoxaparin sodium, and various other injectable medications. Amphastar also manufactures active pharmaceutical ingredients (APIs) including insulin, hyaluronidase, and vasopressin through its subsidiaries, and operates a device laboratory for combination products (pre-filled syringes, injection pens, nasal sprays, MDIs, and DPIs). The company operates six manufacturing facilities across the US, China, and France.

Differentiator

Problem solved

Functional benefit

Brands

  • BAQSIMI: Glucagon nasal powder for treatment of severe hypoglycemia - #1 prescribed glucagon in the US
  • Primatene MIST
  • International Medication Systems
  • Armstrong Pharmaceuticals
  • Rextovy
  • Amphadase
  • Cortrosyn

Products and services

  • BAQSIMI® (glucagon nasal powder) Glucagon nasal powder 3 mg; the first and only dry nasal spray to treat very low blood sugar (severe hypoglycemia). Marketed to healthcare providers for patients with diabetes.
  • Primatene® MIST (Epinephrine Inhalation Aerosol) Epinephrine inhalation aerosol 0.125 mg per spray; the only FDA-approved over-the-counter asthma inhaler, sold directly to consumers via retail pharmacies, convenience stores, and online retailers.
  • Iron Sucrose Injection, USP Generic iron replacement injection indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD); available in 50 mg/2.5 mL, 100 mg/5 mL, and 200 mg/10 mL single-dose vials. Sold to hospitals, infusion centers, and nephrology practices.
  • Teriparatide Injection 560 mcg/2.24 mL (250 mcg/mL) teriparatide in a single-patient-use prefilled pen delivering 28 daily doses of 20 mcg; bioequivalent to Eli Lilly's FORTEO, indicated for osteoporosis treatment in postmenopausal women and men at high risk for fracture.
  • Rextovy® (Naloxone HCl Nasal Spray) 4 mg naloxone hydrochloride nasal spray for emergency treatment of opioid overdose; FDA-approved for OTC sale, allowing direct consumer purchase without a prescription at pharmacies, convenience stores, and online retailers.
  • Ipratropium Bromide HFA Inhalation Aerosol (AMP-007) 17 mcg per actuation generic inhalation aerosol bioequivalent to Boehringer Ingelheim's Atrovent HFA, used for maintenance treatment of bronchospasm associated with COPD; first ANDA applicant entitled to 180 days of generic exclusivity.
  • Albuterol Sulfate Inhalation Aerosol 90 mcg/actuation 8.5 g metered dose inhaler used for respiratory treatment; generic inhalation product for hospitals, urgent care, and patients with asthma or COPD.
  • Glucagon for Injection Generic glucagon for injection bioequivalent and therapeutically equivalent to Lilly's Glucagon Emergency Kit; used for treatment of severe hypoglycemia and as a diagnostic aid.
  • Epinephrine Injection, USP (Luer-Jet) Epinephrine 0.1 mg/mL injection in the Luer-Jet delivery system; indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
  • Enoxaparin Sodium Injection Generic low molecular weight heparin (anticoagulant) injection with safety device; used for prevention and treatment of blood clots (DVT/PE) in hospital and outpatient settings.
  • Cortrosyn® (Cosyntropin) for Injection Cosyntropin 0.25 mg with 10 mg mannitol for injection; used for ACTH stimulation testing to diagnose adrenal and pituitary gland disorders such as Addison's disease.
  • Amphadase® (Hyaluronidase Injection, USP) Hyaluronidase injection used for drug dispersion, injectable therapies, surgical applications, aesthetic medicine, and management of skin and ophthalmic disorders.
  • Naloxone Hydrochloride Injection, USP Generic opioid antagonist injection used for emergency treatment of opioid overdose in hospital, emergency, and pre-hospital settings.
  • Active Pharmaceutical Ingredients (APIs) Active pharmaceutical ingredients manufactured at cGMP facilities in Nanjing, China (Amphastar Nanjing Pharmaceuticals) and Eragny-sur-Epte, France (Amphastar France Pharmaceuticals), including Enoxaparin Sodium, Isoproterenol Hydrochloride, Hyaluronidase, Cosyntropin, Human Insulin and insulin analogs, and Vasopressin; supplied to internal operations and external pharmaceutical customers.

Quantifiable outcome

  • BAQSIMI achieved $185.4 million in full-year 2025 revenues, up 46% year-over-year
  • +3 more outcomes

Companies that use Amphastar Pharmaceuticals

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Amphastar Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Amphastar Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Nanjing Hanxin Pharmaceutical Technology Co., Ltd.coreStrategic or Co-development Partner · 12 January 2026Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a synthetic human ACTH analog designated AMP-110, covering the United States and Canada markets. The deal involves a $2 million upfront payment, with potential additional payments of up to $14 million in development milestones, $75 million in sales milestones, and royalty payments capped at $7.5 million annually and $60 million total. AMP-110 is designed for inflammatory and autoimmune conditions and is currently in early-phase clinical development, with the U.S. ACTH market having exceeded $684 million in 2024. The agreement also grants Hanxin a non-exclusive license to certain Amphastar intellectual property for development and commercialization outside the U.S. and Canada.
  • Nanjing Anji BiotechnologyminorStrategic or Co-development Partner · 6 November 2025Amphastar signed a licensing agreement with Nanjing Anji Biotechnology to develop peptides. The partnership expands Amphastar's pipeline development capabilities in the peptide drug space.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Amphastar Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Hikma Pharmaceuticals: Hikma is a global generic injectable, inhalation, and intranasal pharmaceutical manufacturer with a comparable product portfolio across hospital and respiratory channels. It directly overlaps Amphastar's core generics-plus-specialty franchise and similar US distribution model.
  • ANI Pharmaceuticals: ANI is a US specialty generic manufacturer with a strong injectable, inhalation, and niche branded portfolio serving hospital and specialty pharmacies. Closely comparable to Amphastar in business model, customer mix, and product complexity.
  • Lannett: Lannett is a US-focused generic pharmaceutical company with significant presence in sterile injectables and oral solids. Comparable in scale and channel focus, though with a heavier oral generics mix.
  • Endo International: Endo operates a US sterile injectable franchise (through Par Sterile) alongside specialty/branded products. The injectable segment is a direct comparable to Amphastar's IMS hospital business, though Endo's portfolio is broader and includes branded pain and urology franchises.
  • Dr. Reddy's Laboratories: Dr. Reddy's is a major India-based generics manufacturer with a sizable sterile injectable and biosimilar business targeting US hospital channels. Highly comparable to Amphastar across complex generics, injectables, and respiratory products.

Broad incumbents

  • Hospira (Pfizer): Hospira, acquired by Pfizer in 2015, is the largest US sterile injectable manufacturer. It is the broad incumbent against which Amphastar's IMS subsidiary competes in hospital injectables and is a structural benchmark for Amphastar's generic injectable economics.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic drug maker with significant sterile injectable and respiratory (ProAir) franchises. It overlaps Amphastar across generic injectables, MDIs, and biosimilar development, and serves as a broader-sector reference point.
  • Viatris: Viatris (Mylan-Upjohn combination) has a broad generic injectable, biosimilar, and branded specialty portfolio with strong hospital channel presence. Comparable to Amphastar across sterile injectables and complex generics, though materially larger and more diversified.
  • Sandoz: Sandoz, Novartis's generics and biosimilars spin-off, is a leading global player in sterile injectables and biosimilars including insulins. Directly comparable to Amphastar's generic injectable and biosimilar insulin platform at larger scale.

Emerging players

  • Aspen Pharmacare: Aspen is a South Africa-based specialty and generic pharmaceutical company with a growing sterile injectable portfolio and US presence. It is comparable to Amphastar as a non-traditional generics competitor expanding into complex injectables, though smaller in US hospital share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Amphastar Pharmaceuticals social profiles

Digital presence

Amphastar Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amphastar Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

Amphastar Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Amphastar Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amphastar Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amphastar Pharmaceuticals

What does Amphastar Pharmaceuticals do?

Amphastar Pharmaceuticals develops, manufactures, and markets a diversified portfolio of injectable, intranasal, and inhalation pharmaceutical products, including generics, complex biologics, biosimilars, and proprietary drugs. The company sells generic prescription products to hospitals and urgent care settings, OTC branded products such as Primatene MIST and Rextovy through retail channels, and also produces active pharmaceutical ingredients (APIs) for internal and external customers. It operates six cGMP manufacturing and research facilities across the United States, China, and France.

Is Amphastar Pharmaceuticals a public or private company?

Amphastar Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Amphastar Pharmaceuticals founded?

Amphastar Pharmaceuticals was founded in 1996. It employs 251 to 500 people.

Where is Amphastar Pharmaceuticals based?

Amphastar Pharmaceuticals is headquartered in Rancho Cucamonga, United States, in the North America region.

How does Amphastar Pharmaceuticals make money?

Three revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are proprietary/Branded Products and active Pharmaceutical Ingredients (APIs).

Who are Amphastar Pharmaceuticals's main competitors?

Direct peers on record are Hikma Pharmaceuticals, ANI Pharmaceuticals, Lannett, Endo International and Dr. Reddy's Laboratories. Broad incumbents are Hospira (Pfizer), Teva Pharmaceutical Industries, Viatris and Sandoz. Aspen Pharmacare is listed as an emerging player.

Does Amphastar Pharmaceuticals have an API?

No public API is recorded for Amphastar Pharmaceuticals.

What industry is Amphastar Pharmaceuticals in?

Amphastar Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAMPH: Branded growth and 2027 pipeline milestones anchor a peptide-led expansionAMPHastar Pharmaceuticals, a vertically integrated U.S. platform, supports branded products, complex generics, biosimilars, and peptide development, backed by $369M of self-funded R&D over five years. 2026-27 catalysts include branded-product momentum and expected launches and filings across the pipeline.Simply Wall StAmphastar Pharmaceuticals (AMPH) Could Be 18% Overvalued After Strong Q3 Earnings And GuidanceAmphastar Pharmaceuticals reported strong Q3 earnings and Q4 guidance, with high single-digit sales growth and a small impairment charge. The stock trades at a P/E of 12.4x, below peers, but analysts see a fair value of $24.50 versus a last close of $28.87, implying overvaluation. The company could still gain traction if its respiratory, glucagon, and insulin biosimilar products perform well.American Banking and Market NewsAmphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Raised to Strong-Buy at Wall Street ZenWall Street Zen upgraded Amphastar Pharmaceuticals to a strong-buy rating, while other analysts issued mixed ratings. The company reported Q3 adjusted EPS of $1.14, beating estimates, and revenue of $207.61 million, also above estimates. Analysts expect 2.43 EPS for the current year.In VivoPrimatene Mist Third Quarter Sale Give Amphastar $2.7M More Reasons To Protect ExclusivityAmphastar Pharmaceuticals reported Primatene Mist net sales of $31.5 million in Q3, up $2.7 million from the prior quarter. The increase was driven by Q2 price increases and higher in-store volume, with the company protecting its exclusive OTC emergency asthma treatment status.YahooShould Earnings Beat Require Action From Amphastar Pharmaceuticals (AMPH) Investors?Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61 million and net income of $37.76 million, beating consensus. Record sales from BAQSIMI and Primatene Mist drove the beat, while management expanded its share repurchase program. The company projects $839.3 million revenue by 2029, relying on 4.8% annual growth.Seeking AlphaAmphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call TranscriptAmphastar Pharmaceuticals held its Q3 2026 earnings call on November 5, 2026, with CFO Bill Peters and SVP Dan Dischner speaking. The call included forward-looking statements and non-GAAP measures, but no financial results were disclosed in the provided transcript.TradingViewWells Fargo maintains Amphastar Pharma at Equal-Weight, raises price target to $25 from $20Wells Fargo maintained Amphastar Pharma at Equal-Weight and raised its price target to $25 from $20, a 25% increase. The target implies a 9.6% downside from the Nov 5 close of $27.66.Simply Wall StAmphastar Pharmaceuticals (AMPH) On Q3 Results Faces An Overvalued NarrativeAmphastar Pharmaceuticals reported higher Q3 2026 sales, net income, and EPS, but shares trade above analyst targets. Fair value is pegged at $22.50, implying a 23% overvaluation, while the stock closed at $27.66. The company could challenge this view if new respiratory and injectable products gain traction.FinancialContent Business PageAmphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soarsAmphastar Pharmaceuticals reported Q3 2026 revenue of $207.6 million, up 8.2% year-on-year, beating analyst estimates. Adjusted EPS of $1.14 exceeded consensus by 32.8%, and shares rose 7.2% to $29.66. Analysts project 4.6% revenue growth over the next 12 months.